BackZealand Pharma A/S. Overview

Zealand Pharma A/S. Other Current Liabilities

Track Zealand Pharma A/S.'s other current liabilities ($220M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$220.01M

Peer trimmed avg / median

Loading

Zealand Pharma A/S. Other Current Liabilities History

Loading

Zealand Pharma A/S. vs. peers: Other Current Liabilities Comparison

Loading

Zealand Pharma A/S. Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Zealand Pharma A/S. (ZEAL) FAQ

Zealand Pharma A/S. posts a other current liabilities of $220M as of March 2022. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

Other Current Liabilities is one piece of Zealand Pharma A/S.'s financial statement story. At $220M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for ZEAL's other current liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Zealand Pharma A/S.'s other metric pages and overview cover the third.

Judging Zealand Pharma A/S. against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in other current liabilities easier to interpret. Start with $220M here, then scan peer and history charts to see if the gap is persistent.